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Abstract
We studied the relation between prostaglandin analogue use and ocular adnexal features. We used a prospective, cross-
sectional study involving 157 current, 15 past, and 171 never users of prostaglandin analogues. Patients 50 years of age or
older and without conditions affecting ocular adnexal anatomy underwent glaucoma medication use history, external
digital photography and systematic external adnexal exam. Two masked readers assessed the digital photos for upper lid
dermatochalasis and lower lid steatoblepharon using a validated grading scheme. Another masked clinical examiner also
assessed upper lid ptosis, levator muscle function, and inferior scleral show. We performed ordinal logistic regression
analysis accounting for multiple covariates to assess the relation between prostaglandin analogue use and adnexal features.
Multivariable analyses indicated there was a 230-fold increased risk of incremental involution of dermatochalasis (odds ratio
(OR) = 2.30; 95% confidence interval (CI) 1.43–3.69; p=5.44E-04) and a 249-fold increased risk of incremental loss of lower
lid steatoblepharon (OR = 2.49; 95% CI, 1.54–4.03; p= 1.98E-04) associated with current prostaglandin analogue use
(bimatoprost 0.03%, travoprost 0.005%, or latanoprost 0.004%) versus prostaglandin analogue never or past users. Upper lid
ptosis (OR = 4.04; 95% CI, 2.43–6.72; p=7.37E-08), levator dysfunction (OR= 7.51; 95% CI, 3.39–16.65; p=6.74E-07) and
lower lid retraction (OR=2.60; 95% CI, 1.58–4.28; p=1.72E-04) were highly associated with current prostaglandin analogue
use versus prostaglandin analogue never or past users. The associations between prostaglandin analogue use and
deepening of the upper lid sulci and between prostaglandin analogue use and loss of inferior periorbital fat are confirmed
in this multivariable analysis. The associations between prostaglandin analogue use and levator muscle dysfunction and
between prostaglandin analogue use and upper lid ptosis represent significant side effects that could impact visual function
in glaucoma patients.
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Introduction
Prostaglandin analogues (PGAs) are a class of ocular hypoten-
sive agents that lower intraocular pressure (IOP) predominantly by
enhancing uveoscleral outflow [1]. Once daily dosing of either
latanoprost, bimatoprost or travoprost produce $20% IOP
reduction in at least 70% of patients using mixed treatment
comparison analysis [2]. The most common ocular adverse effects
of the PGAs include periocular skin pigmentation, hypertrichosis,
conjunctival hyperemia, iris color change and ocular pruritus [3].
Other less common, but fairly well established side effects of the
PGAs include uveitis, cystoid macula edema, and reactivation of
herpetic eye disease [3]. Observations in monocular users have
revealed a novel set of ocular adnexal changes attributable to
topical PGA therapy; namely, deepening of the upper eyelid sulcus
(DUES), upper lid ptosis, loss of the inferior orbital fat pads, and
enophthalmos, a constellation of symptoms referred to as
prostaglandin-associated periorbitopathy (PAP) [4,5]. PAP, which
can be easily dismissed as age-related adnexal findings in bilateral
users, has been recognized in several small case series involving
both unilateral [6] and bilateral PGA users [7]. Collectively these
series demonstrate that PAP was not an antecedent finding and
that the adnexal changes partially reversed when the PGA was
withdrawn. Furthermore evidence exists that all three members of
the PGA class can be associated with PAP [8,9].
We performed a large cross-sectional study to confirm whether
PAP is clearly associated with PGA application among bilateral
users using a validated grading scheme applied by masked
observers and confirmed by clinical examination. We performed
multivariable analyses to assess whether PAP was independently
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e61638associated with PGA use or whether it was the result of
confounding features such as age, ethnicity, body mass index or
use of other classes of glaucoma medications. We fully categorize
the nature of PAP and assess the strength of association between
PGA use and adnexal changes. The latter finding provides the
physician with an assessment of the extent of PAP among current
users, as this information cannot be readily inferred from the
previously reported case series.
Methods
Ethics Statement
The Human Studies Committee of Massachusetts Eye & Ear
Infirmary approved this study. All participants provided written
informed consent to participate and these forms are retained on
file with the principal investigator (LRP). The informed consent
was witnessed and cosigned by study personnel (usually MS). The
Human Studies Committee of Massachusetts Eye & Ear Infirmary
approved this informed consent process. Furthermore, all study
participants in Figure 1 have given written informed consent, as
outlined in the PLOS ONE consent form, prior to publication of
their photographs.
Description of Study Population
343 patients (186 females and 157 males) were recruited from
the Glaucoma Service and Comprehensive Eye Service at
Massachusetts Eye & Ear Infirmary (MEEI) over the course of
seven months in 2011.
Inclusion/Exclusion Criteria
Patients were excluded from the study if they had the following
conditions that could affect ocular adnexal features: (1) history of
intraocular procedures (aside from childhood strabismus surgery
and prior laser surgery); (2) pregnancy [10]; (3) active adnexal
infection; (4) medical conditions such as thyroid disease, Addison’s
disease, and congenital, myogenic, or neurogenic ptosis; (5) current
use of oral corticosteroids [11] and (6) prior orbital disease or
eyelid surgery. Exclusion criteria were confirmed by taking
patients’ history and analysis of the medical records. Patients age
50 years or older who were able to give informed consent and did
not meet exclusion criteria were eligible for the study.
Validation of a Grading Scheme for Assessment of
Dermatochalasis and Steatoblepharon
We surveyed the external photographic library of an oculoplas-
tic surgeon (SKF) to derive a grading scheme for upper eyelid
dermatochalasis (D) and lower eyelid steatoblepharon, defined as
inferior adnexal extraconal orbital fat herniation (S). We chose
standards for each category from the library. The grading scheme
for D and S centers on the value of zero (Figure 1), which we
defined as no excess upper eyelid skin and no protrusion of the
inferior orbital fat pads, respectively. Specifically, D scores ranged
from 23t o+2( 23=severe excess skin; +2=deep superior sulcus
with absence of excess skin) while S scores ranged from 21t o+2
(21= very prominent fat pads; +2= total hollowing of inferior
periorbital fat). Subsequently, we took 40 preliminary digital
photographs of glaucoma patients not included in this analysis
with a Canon G12 10MP digital camera (Newport News, VA).
Two masked readers graded the digital photos for D and S scores
using the grading scheme described in the Figure 1. Initial intra-
and interobserver agreement of two masked readers was assessed
with the kappa statistic and found to be high for D and S scores
(k$0.74). Once the grading scheme was established we adopted
the following standardized photographing protocol: we took three
external digital photographs (a frontal view and 45 degree lateral
views from the right and left side) of each patient. Photographs
were taken with patients seated at a distance of 24’’ from the
camera prior to the instillation of mydriatic agents. They were
instructed to face the camera directly with their eyelids open,
brows relaxed, and head level with the lens of the camera.
Clinical Examination
After measuring height and weight on each subject, a masked
examiner measured the upper eyelid margin-to-corneal light reflex
distance or MRD 1 (to assign a P, or ptosis score), lower lid
margin-to-corneal light reflex distance or MRD 2 (to assign an I,
Figure 1. Grading Scheme for Dermatochalasis (D) & Steatoblepharon (S). Digital external photographs representing each grade of D and S
for selected participants enrolled in the study.
doi:10.1371/journal.pone.0061638.g001
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assign an L score) in both eyes. Furthermore the examiner assessed
dermatochalasis and steatoblepharon based on the grading scheme
described above and illustrated in Figure 1. This examination
was completed prior to the instillation of dilating drops. To
measure MRD1 and MRD2 the patient was requested to look at
the light source (pen light) and the distances from the corneal light
reflex to the upper eyelid and to the lower eyelid, respectively,
were recorded. Specifically, P scores ranged from 0 (MRD1=
.4 mm) to 4 (MRD1= ,1 mm). I scores ranged from 0 (MRD2
= $2–3 mm) to 4 (MRD2= .6–7 mm). To measure levator
muscle function the patient’s eyebrow was stabilized by pressure
exerted with the examiner’s thumb. The patient was requested to
look fully up, then fully down, while the excursion of the eyelid was
measured against a ruler. L scores ranged from 0 to 4 (0=
$14 mm levator muscle excursion; 4= #5 mm excursion).
Clinical examination did not include exophthalmometry because
all enrollees using PGA administered drops in both eyes. Table 1
shows the range of measurements for MRD 1, MRD 2, and
levator muscle excursion that are based on a standard measure-
ment protocol used in another study and used to assign P, I and L
scores respectively [12].
Data extracted from the medical record
We extracted patient demographic data, past medical history,
and ocular history from the medical record. We obtained a
detailed ocular drug history on each subject using both medical
records and by personal interview. Patient demographic data
included age, sex, and ethnicity. Past medical history included
diagnoses of hypertension and diabetes. Past ocular history
included glaucoma diagnosis, sub-classified into primary open
angle glaucoma, normal tension glaucoma, ocular hypertension,
open-angle glaucoma suspect, exfoliation glaucoma, pigmentary
glaucoma, and chronic angle closure glaucoma. We also assessed
past ocular history for evidence of age-related macular degener-
ation (AMD), prior intraocular laser surgery such as a laser
trabeculoplasty, or laser iridotomy, and childhood strabismus
surgery.
Glaucoma drug use was categorized as being current, past, or
never according to each class of medicine (PGA, beta blocker,
carbonic anhydrase inhibitor, alpha agonist and cholinergic
agent). PGA use was further defined by whether it was latanoprost,
travoprost or bimatoprost (either 0.01% or 0.03%). Finally,
duration of current and time since past glaucoma drug use was
rounded up to the highest month.
Statistical analyses
We performed three interim assessments of interobserver
agreement in digital photograph grading of D and S scores to
rule out reader drift during the course of the study using the kappa
statistic. Interobserver agreement for D and S was found to be
high for both eyes (k$0.73) based on benchmarks proposed for
reliability of categorical data in previous studies [13]. Intraobserver
agreement in photograph grading of D and S over time was
assessed at the midpoint of data collection with the kappa statistic
and was also found to be high for both eyes (k=0.70) [13].
Correlation between clinical and photographic D (R
2$0.86) and S
(R
2$0.71) scores was calculated with Pearson’s correlation
coefficient and was found to be moderate to high in both eyes [13].
Unpaired t-tests assessed the relation between current PGA use
and adnexal features. The right and left eyes were analyzed
separately. Subsequently, we performed ordinal logistic regression
analyses accounting for multiple covariates to assess the relation
between PGA use and scores for adnexal features. Covariates
accounted for in our analyses included age, sex, and ethnicity;
body mass index (kilograms/meter
2); diagnosis of hypertension,
diabetes, glaucoma, and AMD; prior intraocular laser surgery; and
current use of non-PGA medications for the treatment of
glaucoma. We controlled for each of the following categories of
non-PGA medication use individually: topical beta-blockers,
alpha-adrenergic agonists, topical and oral carbonic anhydrase
inhibitors. Only a few patients were on cholinergic medications so
this variable was not included in multivariable analysis. We
assessed the relation between current use of any PGA and D, P, L,
S, and I scores. Subsequently we used current use of specific PGAs
as the exposures of interest in relation to the adnexal features. Too
few patients were using bimatoprost 0.01% for any meaningful
assessment and these patients were excluded from multivariable
analyses. We also analyzed the association of duration of use of any
PGA and past use of any PGA in relation to D, P, L, S, and I
scores. Finally, we repeated analyses for duration of use of
bimatoprost, travoprost, and latanoprost as the exposure of
interest in relation to adnexal features.
We used SAS (v9.2, SAS Institute, Cary, NC) for all statistical
analyses. The nine exposures in our analysis included: current
PGA use, current bimatoprost 0.03% use, current travoprost use,
current latanoprost use, past PGA use, duration of PGA use,
duration of bimatoprost use, duration of travoprost use, and
duration of latanoprost use. The five outcomes in our analysis
included digital D, digital S, clinical P, clinical L, and clinical I
scores. We corrected for multiple comparisons using the
Bonferroni correction as detailed in the footnotes of relevant
tables in the results section. P values considered significant are less
than or equal to 1.11E-03.
Results
The study population consisted of Caucasian (73%), African
American (18%), Hispanic (5%), and Asian patients (3%) with a
mean age of 65.4 6 9.4 years. The distribution of basic
demographic features and medical status stratified by PGA use is
provided in Table 2. Any imbalance in covariates between PGA
users and non-users was adjusted for in ordinal logistic regression
Table 1. Grading Scheme for Marginal Reflex Distance 1, Marginal Reflex Distance 2 and Levator Muscle Excursion.
Ocular Adnexal Anatomy Grade 0 (normal) 1 (good) 2 (fair) 3 (poor) 4 (very poor)
Marginal Reflex Distance1 (mm) $ 4 . 3 $ 2 $ 1 , 1
Marginal Reflex Distance 2 (mm) $ 2–3 . 3–4 . 4–5 . 5–6 . 6–7
Levator Muscle Excursion (mm) $ 14 $ 12–13 $ 9–11 $ 6–8 $ 5
Ptosis of upper eyelid is measured with Marginal Reflex Distance 1 and used to assign a P or ptosis score. Marginal reflex distance 2 values were used to assign an I or
inferior scleral show score. Levator muscle excursion values were used to assign an L score.
doi:10.1371/journal.pone.0061638.t001
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was confirmed by analysis of medical records. 92 (27%) patients
underwent ocular laser surgery such as argon laser trabeculoplasty,
selective laser trabeculoplasty, and laser peripheral iridotomy prior
to participation in the study.
Of 157 patients undergoing treatment with PGAs, 50 patients
were currently using bimatoprost, 43 were using travoprost, and
64 were using latanoprost. Mean duration of current PGA use was
18 months for both eyes and 8% of participants were past users of
PGAs.
Relation of Current Prostaglandin Analogue Use with
Ocular Adnexal Features
Analyses were limited to the right eye as data between eyes was
similar and highly correlated. In multivariable analysis current
PGA use was associated with a 230-fold increased risk of a 1-unit
increase in D score (odd ratio (OR) = 2.30; 95% confidence
interval (CI), 1.43, 3.69) based on masked assessment of digital
external photographs signifying an association with less derma-
tochalasis or DUES (Table 3). The result was highly correlated
with clinical D scores (R
2$0.86). Current use of bimatoprost
0.03% (OR = 3.67; 95% CI, 1.82, 7.40) and current use of
travoprost (OR = 3.43; 95% CI, 1.70, 6.91) were most strongly
associated with higher D score while current latanoprost use (OR
= 1.42; 95% CI, 0.79, 2.57) was not significantly associated with
D score, even though the latter agent was well represented in terms
of percent and duration of use (mean duration 10 months) in this
study sample.
Current PGA use was also associated with a 249-fold increased
risk of a 1-unit increase in S score (OR = 2.49; 95% CI, 1.54,
4.03) based on assessment of digital external photographs
signifying an association with loss of inferior periorbital fat pads
(Table 3). The association was strongest with bimatoprost 0.03%
use (OR = 8.35; 95% CI, 3.94, 17.69). Similar trends were seen
for travoprost and latanoprost use but they were not significant
after accounting for the multiple comparisons made. Similar
results were seen between current PGA use and clinical S score
(OR = 4.23; 95% CI, 2.51, 7.13).
Current PGA use was strongly associated with increased risk of
upper eyelid ptosis as measured by clinical P score (OR = 4.04;
95% CI, 2.43, 6.72) and increased risk of upper lid levator
dysfunction as measured by clinical L score (OR = 7.51; 95% CI,
3.39, 16.65) (Table 3). All PGAs contributed significantly to this
association. Current PGA use was also associated with a 260-fold
increased risk of a 1-unit increase in I score (OR = 2.60; 95% CI,
1.58, 4.28) signifying an association with lower lid retraction. No
specific PGA showed a particularly strong association with
increasing I score.
Relation of Duration of Prostaglandin Use with Ocular
Adnexal Features
Only longer duration of bimatoprost 0.03% use was signifi-
cantly associated with higher D (OR =1.03; 95% CI, 1.01–1.04),
S (OR = 1.04; 95% CI, 1.02–1.06), and L (OR =1.03; 95% CI,
1.01–1.05) scores (Table 4). Thus each 1-month of bimatoprost
0.03% use was associated with a 3%–4% chance of an incremental
increase in D, S, and P scores. Longer duration of travoprost or
latanoprost use was not associated with significantly higher scores
in any category of ocular adnexal features analyzed (Table 4).
Past Use of Prostaglandin with Ocular Adnexal Features
Past use of any PGA was not associated with significantly higher
scores in any adnexal category (p=0.26). Mean duration since use
of any PGA was 42.8 6 34.9 months.
Table 2. Characteristics of Study Participants.
Current Latanoprost
0.005% User (n=64)
Current Travoprost
0.004% User (n=43)
Current Bimatoprost
0.03% User (n=50) Current PGA Nonuser (n=186)
Age (years) 65.7 6 9.7 65.9 6 9.8 65.1 6 9.1 65.3 6 9.3
Ethnicity
Caucasian, % 68 69 60 79
African American, % 24 25 26 12
Hispanic, % 0 6 10 6
Asian, % 8 0 4 3
Female,% 45 54 53 59
Diabetes mellitus, % 17 23 25 15
Hypertension, % 63 47 68 50
BMI in kilogram/meter
2 26.0 6 4.4 26.1 6 3.9 27.5 6 5.5 26.2 6 4.7
Glaucoma, %* 97 98 98 63
Age related macular degeneration, %* 6 9 1 3
Laser surgery, %* 39 20 42 21
Current topical beta blocker use, %* 50 51 53 19
Current oral or topical CAI use, %* 46 41 57 11
Current AA use, %* 37 23 38 7
Current cholinergic use, %* 1 0 2 0
Values are means 6 standard deviation or percentages and are standardized to the age distribution of the study population. *The above parameters refer to the right
eye. Results were similar for the left eye and are not shown. Abbreviations used: PGA= prostaglandin analogue; STD=standard deviation; BMI= body mass index;
CAI= carbonic anhydrase inhibitor; AA=alpha agonist
doi:10.1371/journal.pone.0061638.t002
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This large prospective, cross-sectional study showed associations
between current bilateral PGA use and deepened upper eyelid
sulci, hollowing of the inferior periorbital fat pads, upper eyelid
ptosis with levator muscle dysfunction, and lower lid retraction,
although the latter finding was not particularly robust. These
findings are strongly driven by use of bimatoprost 0.03%, a
formulation that is no longer marketed in the United States on the
Allergan website (see www.lumigan.com). Although previous
studies reported loss of dermatochalasis and inferior orbital fat
pads, the findings of ptosis and levator muscle dysfunction
associated with use of all members of the PGA class have not
been previously emphasized. Interestingly, all the PGA manufac-
turers include a postmarketing statement regarding deepening of
the upper lid sulci but make no mention of loss of lower eyelid
steatoblepharon, levator dysfunction and upper eyelid ptosis
[14,15,16]. This is the first study to account for multiple potential
confounders in assessing the relation between bilateral PGA use
and adnexal features.
The mechanism by which PGAs produce the deepening of the
upper eyelid sulcus and loss of inferior orbital fat pads seems to
involve effects on periorbital adipocytes as first suggested by
Filippopoulous et al [5]. FP-prostanoid receptor activation inhibits
preadipocyte differentiation in several cell lines that are then
prevented from expressing adipocyte-specific genes [5]. Preapo-
neurotic fat biopsies from patients using the various PGAs and
controls demonstrated that mean adipocyte density of bimatoprost
and travoprost treated eyes was significantly higher (p,0.001)
than that of untreated eyes indicating the volume of lipid per cell
was reduced in PGA users [17]. Jayaprakasam and Ghazi-Nouri
Table 3. Multivariable odds ratio (95% confidence interval; p-value) for current prostaglandin analogue (PGA) use associated with
selected ocular adnexal features.
Any PGA Use (n=341)
Bimatoprost 0.03% Use
(n=232)*
Travoprost 0.004% Use
(n=228)**
Latanoprost 0.005% Use
(n=248)***
Digital D Score 2.30 (1.43, 3.69); p=5.44E-04 3.67 (1.82, 7.40); p=2.75E-04 3.43 (1.70, 6.91); p=5.54E-04 1.42 (0.79, 2.57); p=0.24
Digital S Score 2.49 (1.54, 4.03); p=1.98E-04 8.35 (3.94, 17.69); p=3.06E-08 2.18 (1.08, 4.41); p=0.03 1.78 (0.97, 3.25); p=0.06
Clinical P Score 4.04 (2.43, 6.72); p=7.37E-08 5.04 (2.41, 10.56); p=1.80E-05 5.10 (2.42, 10.76); p=1.91E-05 3.53 (1.87, 6.66); p=9.80E-05
Clinical L Score 7.51 (3.39,16.65); p=6.74E-07 14.90 (5.31, 41.79); p=2.84E-07 8.65 (2.92, 25.68); p=1.01E-04 5.25 (1.98, 13.96); p=8.83E-04
Clinical I Score 2.60 (1.58, 4.28); p=1.72E-04 2.75 (1.33, 5.69); p=0.01 2.90 (1.40, 6.01); p=4.27E-03 2.22 (1.19, 4.13); p=0.01
The reported odds ratios (ORs) reflect likelihood of increasing scores. Increasing digital D score reflects loss of upper lid dermatochalasis judged from digital photos.
Increasing digital S score reflects loss of lower lid steatoblepharon judged from digital photos. Increasing clinical P score reflects increasing upper lid ptosis as judged by
a masked clinical observer. Increasing clinical L score reflects worsening levator function as judged by a masked clinical observer. Increasing clinical I score reflects
increasing inferior scleral show as judged by a masked clinical observer.
N Data is for the right eye. Digital scores reflect mean of 2 readers.
N Bonferroni correction calculation: 0.05/9 exposures x 5 outcomes= 1.11E-03. p-values that are significant after Bonferroni correction are in bold.
N ORs are corrected for age, ethnicity, sex, use of other glaucoma medications, ocular disease such as age-related macular degeneration and glaucoma, systemic disease
such as hypertension and diabetes, and history of ocular laser surgery using ordinal logistic regression.
*Patients who were current travoprost users and current latanoprost users were excluded from this analysis. ** Patients who were current bimatoprost users and current
latanoprost users were excluded from this analysis. *** Patients who were current bimatoprost users and current travoprost users were excluded from this analysis.
doi:10.1371/journal.pone.0061638.t003
Table 4. Multivariable odds ratio (95% confidence interval; p-value) for duration of current prostaglandin analogue (PGA) use in
months associated with selected ocular adnexal features.
Duration Any PGA Use
(n=335)
Duration of Bimatoprost 0.03%
Use (n=232)*
Duration of Travoprost
0.004% Use (n=227)**
Duration of Latanoprost
0.005% Use (n=243)***
Digital D Score 1.01 (1.00, 1.01); p=0.06 1.03 (1.01, 1.04); p=3.85E-04 1.01 (1.00, 1.03); p=0.07 1.00 (1.00, 1.01); p=0.33
Digital S Score 1.01 (1.00, 1.02); p=0.01 1.04 (1.02, 1.06); p=2.25E-05 1.00 (0.99, 1.02); p=0.78 1.01(1.00, 1.02); p=0.01
Clinical P Score 1.01 (1.00, 1.02); p=1.54E-03 1.02 (1.01, 1.04); p=2.96E-03 1.02 (1.01, 1.04); p=4.02E-03 1.01 (1.00, 1.02); p=0.01
Clinical L Score 1.01 (1.00, 1.01); p=0.16 1.03 (1.01, 1.05); p=5.24E-04 1.03 (1.01, 1.05); p=0.01 1.00 (0.99, 1.02); p=0.56
Clinical I Score 1.01 (1.00, 1.02); p=0.04 1.01 (1.00, 1.03); p=0.11 1.02 (1.01, 1.04); p=0.01 1.01(1.00,1.02); p=0.17
The reported odds ratios (ORs) reflect likelihood of increasing scores. Increasing digital D score reflects loss of upper lid dermatochalasis judged from digital photos.
Increasing digital S score reflects loss of lower lid steatoblepharon judged from digital photos. Increasing clinical P score reflects increasing upper lid ptosis as judged by
a masked clinical observer. Increasing clinical L score reflects worsening levator function as judged by a masked clinical observer. Increasing clinical I score reflects
increasing inferior scleral show as judged by a masked clinical observer.
N Data is for right eye. Digital scores reflect mean of 2 readers.
N Bonferroni correction calculation: 0.05/9 exposures65 outcomes= 1.11E-03. p-values that are significant after Bonferroni correction are in bold.
N ORs are corrected for age, ethnicity, sex, use of other glaucoma medications, ocular disease such as age-related macular degeneration and glaucoma, systemic disease
such as hypertension and diabetes, and history of ocular laser surgery using ordinal logistic regression.
*Patients who were current travoprost users and current latanoprost users were excluded from this analysis. ** Patients who were current bimatoprost users and current
latanoprost users were excluded from this analysis. *** Patients who were current bimatoprost users and current travoprost users were excluded from this analysis.
doi:10.1371/journal.pone.0061638.t004
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atrophy in bimatoprost and travoprost users [18].
The mechanism of ptosis and levator muscle dysfunction in
PGA users is unknown. One mechanism may involve chemical
dehiscence of the levator muscle from the superior tarsal plate. In a
retrospective study of floppy eyelid syndrome, immunohistochem-
istry of eyelid biopsy specimens demonstrated increased immuno-
reactivity for elastolytic proteases, particularly matrix metallopro-
teinase (MMP) 7 and MMP 9 [19]. Weinreb et al. demonstrated
that prostaglandin F2a exposure increased production of MMP 1,
MMP 2, MMP 3, and MMP 9 by ciliary body smooth muscle cells
[20]. Furthermore, Ooi et al. treated isolated human ciliary body
smooth muscle cells with free acid forms of bimatoprost,
latanoprost, and unoprostane and found that these PGAs
increased concentrations of MMP-1, MMP-3, and MMP-9 [21].
A contrary view and one that fits with our clinical impression is
that low grade dermatitis, erythema, and hyperpigmentation of the
lid tissue produces lid tightening which in turn makes the lid stiff
and ptotic.
Lower eyelid retraction was the least prominent effect we
observed with PGA use (OR = 2.60; 95% CI, 1.58, 4.28) and
probably needs to be studied with a larger sample size.
Nonetheless we speculate that the modest lower lid retraction we
observed is related to contraction of smooth muscle in the lower
eyelid. There is evidence that the PGAs, especially bimatoprost,
are potent agonists in stimulating contraction of human ciliary
smooth muscle although, admittedly similar studies of eyelid
smooth muscle have not been performed [22].
Our results are consistent with Aihara et al. [23] who performed
the first prospective study of the incidence of DUES after use of
bimatoprost in twenty-five open-angle glaucoma patients. Patients
were switched from latanoprost to bimatoprost and observed over
6 months with external photographs. At 3 and at 6 months, 60%
(15 out of 25) of the patients had DUES as judged photograph-
ically by three examiners [23]. Specifically, the study by Aihara et
al. and our study both show that prostaglandin associated
periorbitopathy (PAP) is pervasive as indicated by the high
incidence rate in their study and the high odds ratio we found for
DUES in current bimatoprost users (OR = 3.67; 95% CI, 1.82,
7.40). Another study by Inoue et al. also found DUES to be most
common among bimatoprost users [24]. The effect seems to
develop soon after starting treatment with bimatoprost 0.03%. For
example we found that the odds ratio for an incremental increase
in D score for current bimatoprost 0.03% users was 3% per month
of use (OR = 1.03; 95% CI, 1.01–1.04). Interestingly we did not
see a significant duration effect for chronic travoprost or chronic
latanoprost use, perhaps because our sample size may not have
been adequate and/or because these latter agents require longer
time to produce adnexal tissue changes.
Overall, our study has several strengths. To our knowledge, this
is the largest, prospective study of the association between bilateral
PGA use and select ocular adnexal features performed thus far.
The grading scheme we constructed to assess digital photographic
D and S was validated with high interobserver agreement prior to
the start of data collection and digital grading. Both clinical
examiners and digital photograph readers were masked to
glaucoma diagnosis and history of PGA use in study participants.
Analyses were adjusted for many key covariates, including age,
gender, ancestry, body mass index (BMI), the use of glaucoma
medications other than PGAs, and glaucoma diagnosis. We were
able to demonstrate that the associations we studied were strongest
with bimatoprost 0.03%, a formulation that has a higher
concentration than the other PGAs. This is consistent with the
results of preaponeurotic fat pad biopsies performed by Park et al.
that showed significantly higher fat cell densities in bimatoprost
users [17]. Furthermore, we showed that longer duration of use of
bimatoprost is associated with higher D, S, and L scores. This is
important because even if our digital readers and clinical
examiners unknowingly unmasked themselves by detecting other
signs of PGA use (e.g., hypertrichosis, periorbital skin pigmenta-
tion), they could not have known about the duration of PGA use.
One limitation of this study is that we could not recruit sufficient
number of bimatoprost 0.01% users to perform meaningful
analyses. Preliminary studies indicate that bimatoprost 0.01%
has acceptable IOP efficacy and as bimatoprost 0.03% users are
converted to the lower dose, it will be important to assess the effect
of bimatoprost 0.01% on adnexal features [25,26]. Furthermore,
because the study is cross-sectional, we were not able to analyze
the reversibility of ocular adnexal changes. Finally the cross-
sectional nature of study does not give an accurate estimate for the
attack rate for PAP. Despite these caveats, the high odds ratios and
significant p-values after Bonferroni correction for multiple
comparisons speak to the biological relevance of the correlations
we found and suggest that PAP is common.
These observations regarding PAP raise several concerns about
the medical management of patients diagnosed with glaucoma.
With regard to patients newly starting anti-glaucoma eye
medications, it is beneficial to inform patients of ocular adnexal
changes that can occur with PGA use. We advise caution before
starting PGAs unilaterally because of the potential to induce
asymmetry in ocular adnexal anatomy. When managing glaucoma
in current PGA users, if the PGA is not adequately lowering IOP,
it is reasonable to replace it with a non-PGA anti-glaucoma
medication. Finally the risks of continued use of PGAs should be
carefully weighed in those patients with inferior visual field loss as
the later development of upper eyelid ptosis could compromise
visual function.
In conclusion, this work demonstrates that PAP is fairly
common and consists of findings that extend beyond DUES to
include loss of lower lid steatoblepharon, upper lid levator
dysfunction and upper lid ptosis. We suspect that PGA-associated
upper lid ptosis is not reversible but more study is needed on this
subject. Latanoprost use produced the least amount of periorbital
fat loss but it too was associated with upper lid ptosis. More
longitudinal analysis of PGA users is indicated.
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